Form 4: Lyra Therapeutics CEO Maria Palasis Receives 300,000 Restricted Stock Units
SEC Form 4 Filing
Lyra Therapeutics' President and CEO, Maria Palasis, was granted 300,000 restricted stock units (RSUs) on October 16, 2024.
Summary
- Maria Palasis, President and CEO of Lyra Therapeutics, received an award of 300,000 restricted stock units (RSUs) on October 16, 2024.
- Each RSU represents the right to receive one share of Lyra Therapeutics' common stock.
- The RSUs will vest in three equal installments on April 1, 2025, October 1, 2025, and April 1, 2026, contingent upon Palasis' continued service to Lyra Therapeutics.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and signals confidence in the CEO's leadership. The vesting schedule promotes long-term commitment.
Positives
- The grant of RSUs to the CEO aligns her interests with those of the shareholders, incentivizing her to drive long-term value creation.
- The vesting schedule encourages continued service and commitment from the CEO.
Risks
- The value of the RSUs is dependent on the future performance of Lyra Therapeutics' stock, which is subject to market risks and company-specific factors.
- If Maria Palasis leaves the company before the vesting dates, she will forfeit the unvested RSUs.
Future Outlook
The vesting of the RSUs is contingent upon the CEO's continued service, suggesting an expectation of her continued leadership at Lyra Therapeutics.
Industry Context
Grants of restricted stock units are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Stakeholder Impact
- Shareholders: The RSU grant aligns the CEO's interests with shareholder value creation.
- Employees: The grant may boost employee morale by demonstrating confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 10/16/2024 | Date of the transaction: Maria Palasis received 300,000 RSUs. |
| 04/01/2025 | First vesting date for the RSUs. |
| 10/01/2025 | Second vesting date for the RSUs. |
| 04/01/2026 | Third vesting date for the RSUs. |
| 10/18/2024 | Date of the Form 4 filing. |
Keywords
Lyra Therapeutics, Maria Palasis, restricted stock units, RSUs, stock options, executive compensation, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.